Investment case
Replimune Group, Inc.
REPL · 2 developments mapped · last assessed 2026-08-14
Market Ontology has mapped 2 macro, policy, and market developments to Replimune Group, Inc. since 2026-08-14. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for REPL yet, so no modelled value is shown. The REPL valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run REPL on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Replimune Group, Inc. Follow-On — $150M
Enhanced financial stability and ability to execute strategic growth initiatives.
· Moves time to market for tudriqev, peak sales potential of tudriqev, risk of clinical trial failure
- Open question
Replimune Group, Inc. Follow-On — $150M
Direct equity dilution and increased cash reserves for operational funding.
· Moves future cash burn rate, probability of successful commercialization, discount rate (due to reduced financing risk)
What changed, by assumption
- 2026-08-14Replimune Group, Inc. Follow-On — $150M
- 2026-08-14Replimune Group, Inc. Follow-On — $150M
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-10 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-08-10 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
| 2026-06-29 | Net debt | Bullish | Cash balance decreased from $483.8M to $268.9M year-over-year due to operating burn. | 0.90 |
| 2026-06-29 | Revenue | Bullish | FDA goal date of August 2, 2026 for RP1 BLA resubmission could lead to first commercial revenue. | 0.80 |
| 2026-06-29 | Net debt | Bullish | Cash and short-term investments decreased from $483.8M to $268.9M year-over-year due to high operating burn. | 0.90 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-08-14 | Replimune Group, Inc. Follow-On — $150M | Bullish | 3-12m | 0.60 |
| 2026-08-14 | Replimune Group, Inc. Follow-On — $150M | mixed | 1-3m | 0.70 |